Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 33, 2020 - Issue 3
123
Views
1
CrossRef citations to date
0
Altmetric
Review Articles

Cannabidiol primer for healthcare professionals

, MD & , MD

  • Scheau C, Badarau IA, Mihai LG, et al. Cannabinoids in the pathophysiology of skin inflammation. Molecules. 2020;25(3):652. doi:10.3390/molecules25030652.
  • Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015;23(7):1377–1385. doi:10.1016/j.bmc.2015.01.059.
  • Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516–525. doi:10.1016/j.biopsych.2015.07.028.
  • Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 2015;12(4):692–698. doi:10.1007/s13311-015-0374-6.
  • Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron. 2012;76(1):70–81. doi:10.1016/j.neuron.2012.09.020.
  • Morena M, Patel S, Bains JS, Hill MN. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology. 2016;41(1):80–102. doi:10.1038/npp.2015.166.
  • Patel S, Hill MN, Cheer JF, Wotjak CT, Holmes A. The endocannabinoid system as a target for novel anxiolytic drugs. Neurosci Biobehav Rev. 2017;76(Pt A):56–66. doi:10.1016/j.neubiorev.2016.12.033.
  • Zamberletti E, Gabaglio M, Parolaro D. The endocannabinoid system and autism spectrum disorders: insights from animal models. Int J Mol Sci. 2017;18(9):1916. doi:10.3390/ijms18091916.
  • Chiurchiu V, van der Stelt M, Centonze D, Maccarrone M. The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: clues for other neuroinflammatory diseases. Prog Neurobiol. 2018;160:82–100. doi:10.1016/j.pneurobio.2017.10.007.
  • Lutz B, Marsicano G, Maldonado R, Hillard CJ. The endocannabinoid system in guarding against fear, anxiety and stress. Nat Rev Neurosci. 2015;16(12):705–718. doi:10.1038/nrn4036.
  • Huang WJ, Chen WW, Zhang X. Endocannabinoid system: role in depression, reward and pain control (Review). Mol Med Rep. 2016;14(4):2899–2903. doi:10.3892/mmr.2016.5585.
  • Donvito G, Nass SR, Wilkerson JL, et al. The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacology. 2018;43(1):52–79. doi:10.1038/npp.2017.204.
  • Masocha W. Targeting the endocannabinoid system for prevention or treatment of chemotherapy-induced neuropathic pain: studies in animal models. Pain Res Manage. 2018;2018:5234943doi:10.1155/2018/5234943.
  • Fulmer ML, Thewke DP. The endocannabinoid system and heart disease: the role of cannabinoid receptor type 2. Cardiovasc Hematol Disord Drug Targets. 2018;18(1):34–51. doi:10.2174/1871529X18666180206161457.
  • Leinwand KL, Gerich ME, Hoffenberg EJ, Collins CB. Manipulation of the endocannabinoid system in colitis: a comprehensive review. Inflamm Bowel Dis. 2017;23(2):192–199. doi:10.1097/MIB.0000000000001004.
  • Pesce M, D'Alessandro A, Borrelli O, et al. Endocannabinoid-related compounds in gastrointestinal diseases. J Cell Mol Med. 2018;22(2):706–715. doi:10.1111/jcmm.13359.
  • Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462. doi:10.1124/pr.58.3.2.
  • Biro T, Toth BI, Hasko G, Paus R, Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. 2009;30(8):411–420. doi:10.1016/j.tips.2009.05.004.
  • Toth KF, Adam D, Biro T, Olah A. Cannabinoid signaling in the skin: therapeutic potential of the “c(ut)annabinoid” system. Molecules. 2019;24(5):918. doi:10.3390/molecules24050918.
  • Ben-Shabat S, Fride E, Sheskin T, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol. 1998;353(1):23–31. doi:10.1016/S0014-2999(98)00392-6.
  • Bonn-Miller MO, ElSohly MA, Loflin MJE, Chandra S, Vandrey R. Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches. Int Rev Psychiatry. 2018;30(3):277–284. doi:10.1080/09540261.2018.1474730.
  • Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770–1804. doi:10.1002/cbdv.200790152.
  • Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med. 2019;8(7):989. doi:10.3390/jcm8070989.
  • Brents LK. Marijuana, the endocannabinoid system and the female reproductive system. Yale J Biol Med. 2016;89(2):175–191.
  • Du Plessis SS, Agarwal A, Syriac A. Marijuana, phytocannabinoids, the endocannabinoid system, and male fertility. J Assist Reprod Genet. 2015;32(11):1575–1588. doi:10.1007/s10815-015-0553-8.
  • Metz TD, Borgelt LM. Marijuana use in pregnancy and while breastfeeding. Obstet Gynecol. 2018;132(5):1198–1210. doi:10.1097/AOG.0000000000002878.
  • Fraguas-Sanchez AI, Martin-Sabroso C, Torres-Suarez AI. Insights into the effects of the endocannabinoid system in cancer: a review. Br J Pharmacol. 2018;175(13):2566–2580.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.